2023 AADOCR/CADR Annual Meeting
The 2023 AADOCR/CADR Annual Meeting & Exhibition provided dental, oral, and craniofacial health scientists with the opportunity to present, discuss, and critique their latest and most cutting-edge research at a 100% in-person gathering in Portland, Oregon. The meeting was attended by 2,054 individuals from 39 countries.The recordings in this library from the meeting are a selection of the science that was presented at the Annual Meeting. These recordings give you the opportunity to participate in the meeting and hear from leading researchers. The recordings include IADR Distinguished Lecture Series speakers and symposia from a collection of scientific groups and networks.
This session can be purchased as part of the full meeting recordings within the product bundles
The International Association for Dental Research is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
Session Description
Approximately 50,000 men and women in the United States will develop head and neck cancer (HNC) in 2022, and the dental profession is typically the first line of defense in early detection of this disease. Both general dentists and specialists can be involved in the multi-disciplinary management of HNC whether it involves screening exams, diagnosis, or treatment. Unfortunately, less than 2/3rds of these patients will survive more than five years, and the annual death rate from HNC approximates that of melanoma and cervical cancer. These figures become even more disheartening when one realizes that multi-modality therapy including ablative/reconstructive surgery, radiation therapy, and chemotherapy can all have significant morbidity.
Cancer immunotherapy has arisen as an exciting new treatment modality for HNC, built on an increased understanding of tumor immunology over the last two decades. However, as immunotherapy moves from an exciting experimental approach to front-line treatment for many cancer types, it has become clear that not all tumors are created equal when it comes to their immune profiles. Some patients’ tumors have learned to armor themselves against immunologic attack by shutting down anti-tumor immune responses and remodeling both their physico-mechanical and immunological microenvironment, making them resistant to immunotherapy.
Thus, there is a need to better understand the complex tumor microenvironment, in order to more accurately determine prognosis and design therapeutic strategies capable of rendering tumors susceptible to immunotherapy and the immunologic effects of conventional therapies.
The purpose of this symposium is to provide a high-level overview of exciting developments in understanding the tumor microenvironment, both in terms of the complex immunosuppressive mechanics of the extracellular matrix, the creation of an immune tolerogenic niche at cancer initiation, and how novel immunotherapeutic strategies can target the adverse the tumor immune microenvironment in head and neck cancer. A broad spectrum of expertise will be represented by our featured clinician-scientist speakers: topics will include current challenges in HNC surgical oncologic ablation strategies and formation of the immune tolerogenic niche at cancer initiation. This will be followed by novel strategies to target fibrotic inflammation and biomaterial-based strategies for cancer immunotherapy and delivery of therapeutics to the immunosuppressive tumor microenvironment.
This symposium will target dental students, post-graduate students, dentists, dentist-scientists, and scientists who wish to expand their knowledge of the tumor immune microenvironment and how cancer immunotherapy will impact head and neck cancer patients. This session will be geared towards clinicians and researchers alike.
Learning Objectives
Saturday, March 18, 2023
Presenters
Dental Materials, Oral Medicine & Pathology, Oral & Maxillofacial Surgery Research, Microbiology/Immunology
CE Credits
1.5 Hours
Financial Interest Disclosure:
Dr. Simon Young is on clinical advisory board of Proteocyte Inc. and is running a clinical study with this company. He is also a consultant for Amend Surgical. Dr. Kyle Vining has Intellectual Property licensed to Amend Surgical. Dr. Leo Lei is on the KOL advisory board for Brooklyn Immunotherapeutics Inc. He is also a co-founder and serves on the advisory panel for Saros Therapeutics Inc. He has licensed the NOOC1 model to Kerafast Inc.
Approximately 50,000 men and women in the United States will develop head and neck cancer (HNC) in 2022, and the dental profession is typically the first line of defense in early detection of this disease. Both general dentists and specialists can be involved in the multi-disciplinary management of HNC whether it involves screening exams, diagnosis, or treatment. Unfortunately, less than 2/3rds of these patients will survive more than five years, and the annual death rate from HNC approximates that of melanoma and cervical cancer. These figures become even more disheartening when one realizes that multi-modality therapy including ablative/reconstructive surgery, radiation therapy, and chemotherapy can all have significant morbidity.
Cancer immunotherapy has arisen as an exciting new treatment modality for HNC, built on an increased understanding of tumor immunology over the last two decades. However, as immunotherapy moves from an exciting experimental approach to front-line treatment for many cancer types, it has become clear that not all tumors are created equal when it comes to their immune profiles. Some patients’ tumors have learned to armor themselves against immunologic attack by shutting down anti-tumor immune responses and remodeling both their physico-mechanical and immunological microenvironment, making them resistant to immunotherapy.
Thus, there is a need to better understand the complex tumor microenvironment, in order to more accurately determine prognosis and design therapeutic strategies capable of rendering tumors susceptible to immunotherapy and the immunologic effects of conventional therapies.
The purpose of this symposium is to provide a high-level overview of exciting developments in understanding the tumor microenvironment, both in terms of the complex immunosuppressive mechanics of the extracellular matrix, the creation of an immune tolerogenic niche at cancer initiation, and how novel immunotherapeutic strategies can target the adverse the tumor immune microenvironment in head and neck cancer. A broad spectrum of expertise will be represented by our featured clinician-scientist speakers: topics will include current challenges in HNC surgical oncologic ablation strategies and formation of the immune tolerogenic niche at cancer initiation. This will be followed by novel strategies to target fibrotic inflammation and biomaterial-based strategies for cancer immunotherapy and delivery of therapeutics to the immunosuppressive tumor microenvironment.
This symposium will target dental students, post-graduate students, dentists, dentist-scientists, and scientists who wish to expand their knowledge of the tumor immune microenvironment and how cancer immunotherapy will impact head and neck cancer patients. This session will be geared towards clinicians and researchers alike.
Learning Objectives
- Provide members of the audience with a description of the complex tumor immune and mechanical microenvironment and how cancer cells interact with both immune and stromal cells in the context of immune escape.
- Discuss the concept of immunotherapy and novel immunotherapy-based approaches in cancer treatment.
- Highlight the potential of cross-discipline collaboration in immunotherapy by engaging various disciplines of basic and translational research, as well as, clinician-scientists, and clinicians.
Saturday, March 18, 2023
Presenters
- Ashish Patel - Challenges in ablative surgical oncology
- Yu Leo Lei - Resolving an immune tolerogenic niche at the earliest phase of cancer initiation
- Kyle Holmberg Vining - Targeting Fibrotic Inflammation
- Di Wen - Adipocytes and ROS-responsive hydrogels for drug delivery and cancer immunotherapy
Dental Materials, Oral Medicine & Pathology, Oral & Maxillofacial Surgery Research, Microbiology/Immunology
CE Credits
1.5 Hours
Dr. Simon Young is on clinical advisory board of Proteocyte Inc. and is running a clinical study with this company. He is also a consultant for Amend Surgical. Dr. Kyle Vining has Intellectual Property licensed to Amend Surgical. Dr. Leo Lei is on the KOL advisory board for Brooklyn Immunotherapeutics Inc. He is also a co-founder and serves on the advisory panel for Saros Therapeutics Inc. He has licensed the NOOC1 model to Kerafast Inc.
